MSF urges EU to rid market of ‘avoidable suffering’ from SPCs
30-11-2020
The Indian Patent Office has approved pharmaceutical company Pfizer’s application to patent its Prevenar 13 (pneumococcal 7-valent conjugate) drug, despite claims by Médecins Sans Frontières (MSF) that it is too obvious.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Pfizer, pneumonia, patent, MSF, Indian Patent Office